Dr Natalia Gandur speaks to ecancer about the updates in renal cancer from ASCO 2026.

She explains that this year the general theme focused on refining adjuvant treatment decisions through improved risk stratification, biomarker development, and broader evidence across renal cancer subtypes.

Dr Gandur covers adjuvant RCC and biomarkers, radical treatment approaches for oligometastatic disease, non-clear cell renal cancer, and patient-centred future directions.